ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.

ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.

Hypoxia-inducible factor (HIF) is an attractive therapeutic target for renal cell carcinoma (RCC) as its high expression due to the loss of von Hippel-Lindau (VHL) promotes RCC progression. Considering this, we hypothesized that ELR510444, a novel orally available small molecule inhibitor of HIF act...

Full description

Bibliographic Details
Main Authors: Jennifer S Carew, Juan A Esquivel, Claudia M Espitia, Christoph M Schultes, Marcel Mülbaier, Joe D Lewis, Bernd Janssen, Francis J Giles, Steffan T Nawrocki
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3266297?pdf=render

Internet

http://europepmc.org/articles/PMC3266297?pdf=render

Similar Items